BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230215
DTEND;VALUE=DATE:20230218
DTSTAMP:20260429T185530
CREATED:20230111T132555Z
LAST-MODIFIED:20230111T154919Z
UID:30279-1676419200-1676678399@senzagen.com
SUMMARY:PCHi 2023 Expo & SHSOT Forum
DESCRIPTION:Personal Care and Homecare Ingredients 2023 Expo & Shanghai Society of Toxicology Forum\n15-17 February 2023 @The China Import and Export Fair Complex\, Guangzhou\, China\nRead More
URL:https://senzagen.com/event/pchi-2023-expo-shsot-forum/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/msg98-1-2022-07-21-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260429T185530
CREATED:20221021T092257Z
LAST-MODIFIED:20221128T115912Z
UID:29974-1669852800-1670025599@senzagen.com
SUMMARY:2022 Aromadays
DESCRIPTION:Dec 1-2 | Avignon\, Palais des Papes\, France\nMeet us at the 2022 Aromadays conference in Avignon and talk to our specialists regarding the application of the GARD assays for essential oils. \nScientific session\n09:45 CET\, Dec 2\, 2022\nAre there limitations to the applicability of toxicological tests to essential oils ? Focus on the GARD®skin test\nExiste-t-il des limites à l’application des tests toxicologiques aux Huiles Essentielles? Focus sur le test GARD®skin\nCristina ONCINS PALLAS\, Chargée de l’évaluation toxicologique des ingrédients – CONSORTIUM HE\nDr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen\nRead more here
URL:https://senzagen.com/event/2022-aromadays/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/10/logo_aromadays.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221124T080000
DTEND;TZID=Europe/Stockholm:20221125T170000
DTSTAMP:20260429T185530
CREATED:20221102T083023Z
LAST-MODIFIED:20221121T123857Z
UID:30037-1669276800-1669395600@senzagen.com
SUMMARY:2022 SFT
DESCRIPTION:Nov 24-25 | Avignon\, France\nMeet us at the 2022 annual meeting of the French Society of Toxicology in Avignon and talk to our skin sensitization experts regarding the new opportunities the GARD assays have brought to the field. \nWe will also present a poster: “Quantitative sensitizing potency assessment using GARD®skin Dose-Response”. \nPresented by: Dr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen
URL:https://senzagen.com/event/2022-sft/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/logo_sft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221126
DTSTAMP:20260429T185530
CREATED:20220825T140904Z
LAST-MODIFIED:20221114T140547Z
UID:29773-1668988800-1669420799@senzagen.com
SUMMARY:2022 ESTIV
DESCRIPTION:Booth#5 | Nov 21-25 | Sitges (Barcelona)\, Spain\nAre you attending the 2022 ESTIV International Congress? Come meet us at our booth and join our scientific sessions to hear the latest news about GARD and how the assays are used for skin sensitization testing. We will also introduce you to our expanded services for in vitro regulatory toxicity testing and how you can use in vitro methods for the biological evaluation of medical devices. \n\nScientific presentations\n\n“In vitro assessment of skin sensitizing potential of process-related impurities in polymeric materials during product development”\nSpeaker:  Dr Andy Forreryd @SenzaGen \nTuesday\, November 22nd\, 2022\, 11:00-13:00 | Session 3a. Models\, biomarkers and assays for systemic and immune toxicity \n“Biocompatibility of medical devices: eye irritation of preserved and unpreserved eye drops on HCE model”\nSpeaker:  Dr Laura Ceriotti @VitroScreen \nThursday\, November 24th\, 2022\, 11:00-12:40| Session 8a – In vitro methods for safety assessment of medical devices \n\n\nPosters\n\n\nJoint poster with Sonova: #307 – “In vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices”\nPoster presentation by Dr Rose-Marie Jenvert @SenzaGen \nSession 8a. In vitro methods for safety assessment of medical devices \nJoint poster with Coty: #275 – “Effect of a modulator on the skin sensitization potency of cosmetic fragrance formulations”\nPoster presentation by Dr Carine Linossier @Coty \nSession 4b. Local toxicity testing (safety and efficacy) \n  \n 
URL:https://senzagen.com/event/2022-estiv/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/ESTIV_Screenshot-2022-08-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221019
DTEND;VALUE=DATE:20221022
DTSTAMP:20260429T185530
CREATED:20220825T135715Z
LAST-MODIFIED:20220825T135806Z
UID:29760-1666137600-1666396799@senzagen.com
SUMMARY:2022 ASCCT
DESCRIPTION:Oct 19-21 | Chapel Hill\, N.C.\,USA\nMore information coming soon!
URL:https://senzagen.com/event/2022-ascct/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/22179-RAD-ASCCT-11th-Annual-Meeting-Graphics-Banner-CROPPED-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260429T185530
CREATED:20220707T081238Z
LAST-MODIFIED:20220926T135947Z
UID:29631-1664928000-1665100799@senzagen.com
SUMMARY:2022 Biocompatibility Matters
DESCRIPTION:Oct 5-6 | Copenhagen\, Denmark\nMeet SenzaGen at 2022 Biocompatibility Matters\, a two-day conference in Copenhagen. SenzaGen’s Medical Device specialist and ISO expert Dr Rose-Marie Jenvert will speak on the topic “New approaches to in vitro sensitization – regulatory acceptance”. \n\nKey takeaways:\n\n* An introduction to in vitro assays for skin sensitization\, ISO 10993-10\n* The potential to use polar and non-polar extracts in in vitro assays\n* How in vitro assays can gain regulatory acceptance\n* Case studies on in vitro skin sensitization assessment of medical devices \n\nRead more and register\n\n 
URL:https://senzagen.com/event/2022-biocompatibility-matters/
LOCATION:Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/07/BM-logo@2x-e1622186428171.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220922
DTSTAMP:20260429T185530
CREATED:20220427T123124Z
LAST-MODIFIED:20220916T085253Z
UID:29390-1663718400-1663804799@senzagen.com
SUMMARY:2022 ICT/IUTOX/EUROTOX
DESCRIPTION:2022 International Congress of Toxicology – “Uniting in Toxicology”\n\nDiscussions at this year’s ICT\nNew opportunities for skin sensitization testing with GARDskin OECD TG 442E\n\nCome visit us at our booth and join our industry symposium to learn how the high performance and broad applicability of the GARDskin method bring new opportunities to the field of in vitro skin sensitization testing. We will provide user cases to show how GARD can be used to fill data gaps during regulatory testing and R&D. \n\nIndustry symposium\nNew GARD data on “difficult-to-test” substances and potency assessment\n\nSep 20\, 12:00-13:00 CEST @Room 0.09 Athens\n \nREGISTER HERE TO SECURE YOUR SEAT\n(click the link or fill out the form below)\nFill out my online form.\n \n\nHighlights at our booth #34\nDiscover our expanded in vitro toxicity testing services\n\nDo you have “difficult-to-test” samples or are you looking for quantitative skin sensitizing potency information? Come discuss your testing needs with us and learn more about GARD and our expanded in vitro toxicity testing services for cosmetics\, chemicals and medical devices. \nFIND OUT ABOUT OUR SERVICES AND EXPERTISE
URL:https://senzagen.com/event/2022-ict-iutox-eurotox/
LOCATION:Maastricht
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/04/LIME-banner-v7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220914T143000
DTEND;TZID=Europe/Stockholm:20220914T180000
DTSTAMP:20260429T185530
CREATED:20220825T134032Z
LAST-MODIFIED:20220826T062417Z
UID:29741-1663165800-1663178400@senzagen.com
SUMMARY:2022 MVA MedTech Network meeting
DESCRIPTION:Drug device combination products and substance-based medical devices\nSep 14 | Copenhagen\, Denmark\nMedicon Valley Alliance\, together with member company Innokas Medical\, have the pleasure to invite you to the Medicon Valley Alliance MedTech Network meeting\, on the 14th of September\, focusing on drug-device combination products and substance-based medical devices. \n\nSign up here\n\nThe market for drug-device combination products is growing and it is anticipated that up to one in three medical products in development is a combination of a drug/substance and a MedTech product. Drivers for the growth in combination products is the rise of patients suffering from chronic diseases such as diabetes\, cancer\, and respiratory problems as well as growth in the home-based health care market and technological advancements. \nWhen searching for the correct regulatory approval in the EU the primary mode of action (PMOA) will define the regulatory path for your products. For example\, if the action of your medicinal substance is ancillary\, then your product is regulated as a medical device under MDR\, on the other hand\, if the product is mainly of the medicinal substance the product will be regulated as a medicinal product.  A substance with a therapeutic effect can be either a medicinal product/drug or a medical device\, depending on its primary mechanism of action. \nDeveloping this type of products is associated with a high level of complexity. For combination products\, you need to navigate two of the most intensely regulated pathways in one go: for pharmaceuticals and medical devices. The re-classification of substance-based medical devices according to MDR means a more extensive risk assessment involving scientific evidence of PMOA. \nIn this MVA MedTech Network meeting\, we would like to invite you to hear from experts in the area of developing drug-device combination products and substance-based medical devices as well as hearing from companies sharing their experiences\, challenges and solutions.\nIf you are interested in sharing your company’s approach and experiences with drug-device combination products and/or substance-based medical devices and to speak at the meeting on the 14th of September\, please reach out to Sofia Norås\, sn@mva.org. \nAgenda\n14.30 – 15.00  Registration\, networking and light refreshments\n15.00 – 15.10  Welcome\, Anette Steenberg\, CEO\, Medicon Valley Alliance; Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.10 – 15.15  IP and patents in combination products\, Pernille Winding Gojkovic\, CEO\, Høiberg European Patent Attorneys\n15.15 – 15.45  Challenging development with combination products\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.45 – 16.05  Substance-based medical devices\, Rose-Marie Jenvert\, Product Manager GARD applications SenzaGen\n16.05 – 16.40  Company cases TBC\n16.40 – 17.00  Concluding remarks: Building collaborations between organisations & Q&A to all speakers\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n17.00 – 18.00  Networking
URL:https://senzagen.com/event/2022-mva-medtech-network-meeting/
LOCATION:Medicon Valley Alliance\, Auditorium\, Arne Jacobsens Alle 15 \, 2300 Ørestad City\, Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/220914-medtech-network-banner-1080.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260429T185530
CREATED:20220224T104229Z
LAST-MODIFIED:20220224T105153Z
UID:28967-1649116800-1649375999@senzagen.com
SUMMARY:in-cosmetics Global
DESCRIPTION:The leading global event for personal care ingredients\nApril 5-7 | Porte de Versailles\, Paris | Booth: P102\nMeet SenzaGen and partners PKDERM\, GenEvolutioN\, WatchFrog and CEHTRA at in-cosmetics Global in Paris to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients!
URL:https://senzagen.com/event/in-cosmetics-global-2/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/02/Incosmeticsglobal-2022_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220327
DTEND;VALUE=DATE:20220401
DTSTAMP:20260429T185530
CREATED:20211209T133110Z
LAST-MODIFIED:20220321T111837Z
UID:28283-1648339200-1648771199@senzagen.com
SUMMARY:2022 SOT
DESCRIPTION:Meet us at the 2022 SOT Annual Meeting & ToxExpo\nBooth #1207 @ San Diego Convention Center\, San Diego\, USA\nAre you attending the 2021 Society of Toxicology Annual Meeting? Come join our hosted session and poster presentations to hear the latest news about GARD™ and how the assays are used for skin sensitization testing. We will also introduce you to how you can use in vitro methods for the biological evaluation of medical devices.  \n\nExhibitor hosted session\n\nMar 29\, 10:30-11:30 EDT\, Room 23A\nNew GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals:\nTogether with guest speakers from Takasago and Sonova\, our Scientific Liaison Dr Andy Forreryd will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. \n  \n \nBook mark the session in SOT’s event calendar: \nSkin Sensitization: Using In Vitro Tools for Quantitative Potency Assessment as an Alternative to the Local Lymph Node Assay \n  \n\nPosters\n\nLive poster sessions on Mar 28\, 9:00-10:45 EDT\n🎫 P460 | Applicability domain of GARDskin\nThe GARDskin assay: Investigation of the applicability domain of indirectly acting haptens  \n🎫 P850 | Joint poster with Sonova\nIn vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices  \n🎫 P846 | Joint poster with Risk Science Consortium\nAbility of the GARD assay to replace the GPMT and the LLNA for assessment of the skin sensitization potential of medical devices  \n 
URL:https://senzagen.com/event/2022-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/SOT-2022_small-narrow-green.png
END:VEVENT
END:VCALENDAR